Evidence map›Paper›PMID 40423244›Full record

ArticleNeuro-oncology2025

A clinically annotated transcriptomic atlas of nervous system tumors.

Chi H Le, Ajai K Nelson, Adam J Berrones, Janki R Naidugari, Robert P Naftel, Eyas M Hattab, Brian J Williams, Akshitkumar M Mistry

Abstract read
In one paragraph

Article in Neuro-oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Chi H LeSchool of Medicine, Vanderbilt University, Nashville, Tennessee.
Ajai K NelsonOberlin College, Oberlin, Ohio.
Adam J BerronesDivision of Prevention and Quality Improvement, Kentucky Department for Public Health, Frankfort, Kentucky.
Janki R NaidugariSchool of Medicine, University of Louisville, Louisville, Kentucky.
Robert P NaftelDepartment of Neurological Surgery, Vanderbilt University Medical Center, Nashville, Tennessee.
Eyas M HattabDepartment of Pathology and Laboratory Medicine, University of Louisville, Louisville, Kentucky.
Brian J WilliamsDepartment of Neurological Surgery, University of Louisville, Louisville, Kentucky.
Akshitkumar M MistryDepartment of Neurological Surgery, University of Louisville, Louisville, Kentucky.ORCID 0000-0002-7918-5153

Funding

Research Design, Compliance, and Data Management (RDCD)P20GM155899 · NIGMS · UNIVERSITY OF LOUISVILLE · PI Jon Klein · 2024 to 2026
$9.3M
Kentucky Pediatric Cancer Research Trust FundNIGMS NIH HHS P20 GM155899
6 · The paper itself

Abstract

backgroundWhile DNA methylation signatures are distinct across nervous system neoplasms, it has not been comprehensively demonstrated whether transcriptomic signatures exhibit similar uniqueness. Additionally, no large-scale dataset for comparative gene expression analyses exists. This study addresses these knowledge and resource gaps.

methodsWe compiled and harmonized raw transcriptomic and clinical data for neoplastic (n = 5,402) and nonneoplastic (n = 1,973) nervous system samples from publicly available sources, all profiled on the same microarray platform. After adjusting for surrogate variable effects ("batch effects"), machine learning methods were used to visualize, cluster, and reclassify samples with uncertain diagnoses (n = 2,225).

resultsWe generated the largest clinically annotated transcriptomic atlas of nervous system tumors to date. Sample clustering was primarily driven by diagnosis. We show the utility of the atlas by refining the transcriptional subtypes of pheochromocytoma and paraganglioma (PH/PG), revealing 6 robust subtypes (Neuronal, Vascular, Metabolic, Steroidal, Developmental, Indeterminate), which were independently validated using TCGA RNA-seq data and that correlated with specific mutational signatures and clinical behaviors of these tumors.

conclusionsLike bulk DNA methylation, we demonstrate that bulk transcriptomic signatures are distinct across the diagnostic spectrum of nervous system neoplasms. Our atlas' broad coverage of diagnoses, including rarely studied entities, spans all ages and includes individuals from diverse geographical regions, enhancing its utility for comprehensive and robust comparative gene expression analyses, as exemplified by our PH/PG analyses. For access, visit http://kdph.shinyapps.io/atlas/ or https://github.com/axitamm/BrainTumorAtlas.

Indexed as

Biomarkers, TumorGene Expression ProfilingNervous System NeoplasmsTranscriptomeAtlases as TopicDNA MethylationFemaleGene Expression Regulation, NeoplasticHumansMachine LearningMalePrognosisBiomarkers, Tumorbrain neoplasmsgene expressionnervous system neoplasmsparagangliomatranscriptome

Identifiers

PMID40423244
PMCPMC12833534

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.